The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 29, 2020

Filed:

Jan. 10, 2018
Applicant:

Andes Biotechnologies Global, Inc., Burlingame, CA (US);

Inventors:

Luis O. Burzio, Santiago, CL;

Jaime E. Villegas, Santiago, CL;

Veronica A. Burzio, Santiago, CL;

Assignee:

Andes Biotechnologies Global, Inc., Burlingame, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2006.01); C07H 21/04 (2006.01); C12Q 1/6886 (2018.01); C07F 9/6561 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01); C12N 5/09 (2010.01); C12Q 1/6804 (2018.01); C12Q 1/70 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); C07F 9/65616 (2013.01); C12N 5/0693 (2013.01); C12N 15/11 (2013.01); C12N 15/113 (2013.01); C12Q 1/6804 (2013.01); C12Q 1/701 (2013.01); C12Q 1/708 (2013.01); C12N 2310/11 (2013.01); C12N 2310/53 (2013.01); C12N 2330/10 (2013.01); C12N 2501/06 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/158 (2013.01);
Abstract

A novel family of human mitochondrial RNAs, referred to as chimeric RNAs, which are differentially expressed in normal, pre-cancer and cancer cells, are described. Oligonucleotides targeted to the chimeric RNAs are provided. The described oligonucleotides or their analogs can be used for cancer diagnostics and cancer therapy as well as for research. In one embodiment of this invention, these oligonucleotides hybridize with the sense or with the antisense mitochondrial chimeric RNAs, and the result of the hybridization is useful to differentiate between normal proliferating cells, pre-cancer cells and cancer cells. In another embodiment of the invention, the compositions comprise oligonucleotides that hybridize with the human chimeric RNAs resulting in cancer cell and pre-cancer cell death, while there is no effect in normal cells, constituting therefore, a novel approach for cancer therapy.


Find Patent Forward Citations

Loading…